Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites

Francine Durocher, Patricia Tonin, Donna Shattuck-Eidens, Mark Skolnick, Steven A Narod, Jacques Simard

Abstract

Germline mutations in the BRCA1 tumour suppressor gene on chromosome 17q21 are responsible for approximately half of the cases of hereditary breast cancer, including the majority of familial breast/ovarian cancers. To increase our knowledge of the spectrum of BRCA1 mutations, we have extended our analysis to include patients with varied family histories of cancer of the breast, ovary, and at multiple other sites. We have analysed 23 unrelated familial cases using direct sequencing or a combination of dideoxy fingerprinting and sequencing procedures. Twenty one of these families contained three or more cases of breast or ovarian cancer and two families had one case of breast cancer diagnosed before the age of 40 and one case of ovarian cancer. The common frameshift mutation 5382insC was detected in two patients, and the 185delAG mutation was found in a family of Ashkenazi Jewish descent. The novel frameshift mutation 3450del4 (CAAG) was detected in a patient who developed breast cancer at the age of 28 and ovarian cancer at the age of 34. Three other women in this family were diagnosed with breast cancer at the ages of 26, 29, and 40. The novel frameshift mutation 2953del3+C was found in a French Canadian woman who had developed two primary cancers of the breast at the age of 37 and 38 and renal cancer at the age of 38.

(J Med Genet 1996;33:814–819)

Key words: BRCA1; breast cancer; ovarian cancer.

It is estimated that 5% to 10% of breast and ovarian cancer cases may be attributable to dominantly inherited susceptibility genes. Genetic linkage studies have suggested that germline mutations in the BRCA1 gene located on chromosome 17q21 are responsible for approximately 75% of cancers in families with multiple cases of both breast and ovarian cancer. In high risk families, female carriers of BRCA1 mutations have a 80-90% lifetime risk of breast cancer and a 40-50% risk of ovarian cancer, and carriers of both sexes have a four-fold increased risk of colon cancer. Male carriers face a three-fold increased risk of prostate cancer.

The BRCA1 gene contains 5592 bp of coding sequence within 22 exons spread over approximately 70 kb, and encodes an acidic protein of 1863 amino acids, which contains a highly conserved Cys8–His-Cys9 RING finger motif near the amino-terminus. Although the precise function of this protein remains to be elucidated, the loss of the wild type allele in breast tumours from linked families supports the hypothesis that BRCA1 acts as a tumour suppressor gene. Moreover, there are data suggesting that BRCA1 is associated with functional differentiation of mammary epithelial cells whereas it may normally serve as a negative regulator of breast cell growth and its expression is under the control of sex steroid hormones. Furthermore, direct evidence has been recently obtained showing that retroviral transfer of the wild type, but not mutant, BRCA1 gene specifically inhibits growth of all breast and ovarian cancer cell lines tested.

Mutation analysis of the BRCA1 gene for women in families with a high incidence of breast/ovarian cancer is now possible. During the course of the present study, many distinct germline mutations scattered throughout the coding region were detected with no evidence of clustering, while there is evidence suggesting a correlation between their location and the ratio of breast to ovarian cancer incidence in each family. Among the seven distinct mutations that we previously reported in breast/ovarian cancer families ascertained in Canada, four of them, namely 185delAG, 1294del40, 4184del4, and 5382insC, are among the most frequently reported. Haplotype analysis suggests that these recurrent mutations did not occur de novo but are founder mutations sharing common ancestors. It is also relevant to note that families in which BRCA1 mutations were identified frequently contained cases of cancers at sites other than breast and ovary. Therefore, the present study was undertaken to increase our knowledge of the spectrum of BRCA1 mutations in families with cancers of the breast, ovary, and other sites.

Materials and methods

Patient samples

The 23 breast/ovarian cancer families were referred to the McGill University Hereditary Cancer Clinic at the Montreal General Hospital for genetic counselling, risk assessment, or mutation analysis. All subjects signed appro-
Mutation analysis of the BRCA1 gene

Mutation

appropriate informed consent forms for participation in the study. Cases of breast/ovarian cancer were verified by review of pathological material, pathology reports, or death certificate information for at least the index case of each family. Families were selected on the basis of (1) three or more cases of breast cancer or ovarian cancer at any age (21 families), or (2) one case of breast cancer diagnosed before the age of 40 and a case of ovarian cancer (two families). In each family one person was studied for BRCA1 mutations by direct sequencing or a combination of dideoxy fingerprinting and sequencing procedures. In general, this was the youngest case of breast cancer available, or a case of ovarian cancer.

MUTATION ANALYSIS BY DIRECT DNA SEQUENCING

Genomic DNA was extracted from peripheral blood samples from the index case of families 115, 277, 284, 291, 337, 407, 462, and 474. PCR was performed using 25 sets of primers and the same experimental procedures as previously described. After 35 cycles, the primers were removed by selective precipitation, and the PCR products were then subjected to a 35 cycle asymmetrical amplification. Single stranded DNA produced by asymmetrical PCR was sequenced directly by the dideoxy method using the limiting PCR primer or sequence specific primers with the T7 sequencing kit (Pharmacia LKB Biotechnologies), as previously described. The BRCA1 coding exons and exon-intron boundaries were sequenced entirely for each of the eight index cases from the above mentioned families, except for exon 4 which was previously found to be non-coding.

Genomic DNA samples from subjects 6 and 11 from family 291 were used to test for the presence of the 185delAG mutation in exon 2, whereas DNA samples from the index cases No 5 from family 289 and No 22 from family 448 were used to determine the presence of 5382insC in exon 20. PCR was performed using exon 2 or exon 20 primer sets under the same experimental procedures as previously described and the sequence of these BRCA1 exons was determined by direct sequencing of single stranded DNA produced by asymmetrical PCR as previously described.

In order to determine the nature of the novel frameshift mutation 2953del3+C in index case No 18 from family 290, the region overlapping the mutation was amplified by PCR using the forward primer 5’ GTGTGAGTCAGTTGAGCAGCAATA 3’ and the reverse primer 5’ GCCTCTGAACGTAGTATAAG 3’ and then subcloned in the pCRII plasmid using the TA cloning kit (In Vitrogen). The sequence of the PCR fragment was determined in both orientations. The mutation was also found by direct sequencing of the asymmetrical PCR product thus excluding a cloning artefact.

GENOTYPING OF MICROSATELLITE MARKERS WITHIN OR CLOSE TO THE BRCA1 GENE

The four short tandem repeat markers D17S855, D17S1322, D17S1323, and D17S1327 were genotyped in the index cases from each family using standard procedures. Radiolabelled PCR products were electrophoresed on standard 6% polyacrylamide denaturing sequencing gels. The marker
Table 1 Characteristics of 23 cancer families tested for BRCA1 mutations

<table>
<thead>
<tr>
<th>Family</th>
<th>No of cases of breast cancer</th>
<th>No of cases of ovarian cancer</th>
<th>Other cancers</th>
<th>BRCA1 mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>103</td>
<td>2</td>
<td>1</td>
<td>Br</td>
<td>ND</td>
</tr>
<tr>
<td>115</td>
<td>3</td>
<td>2</td>
<td>Br</td>
<td>ND</td>
</tr>
<tr>
<td>117</td>
<td>1</td>
<td>3</td>
<td>Br, Bl, Ki, Lu, Pro, Pau, Thro</td>
<td>ND</td>
</tr>
<tr>
<td>133</td>
<td>11</td>
<td>2</td>
<td>Br, Bl, Ki, Lu, Pro, Pau, Thro</td>
<td>ND</td>
</tr>
<tr>
<td>146</td>
<td>3</td>
<td>0</td>
<td>Mmel, Pan, Os</td>
<td>ND</td>
</tr>
<tr>
<td>195</td>
<td>3</td>
<td>3</td>
<td>BCC, Co, Ki</td>
<td>ND</td>
</tr>
<tr>
<td>273</td>
<td>1</td>
<td>1</td>
<td>Thro</td>
<td>ND</td>
</tr>
<tr>
<td>277</td>
<td>6</td>
<td>1</td>
<td>Pro, Ut</td>
<td>ND</td>
</tr>
<tr>
<td>283</td>
<td>2</td>
<td>1</td>
<td>Pau</td>
<td>ND</td>
</tr>
<tr>
<td>284</td>
<td>3</td>
<td>2</td>
<td>Co, Mmel, Nhl, Pro, Pau, Sk, St</td>
<td>ND</td>
</tr>
<tr>
<td>285</td>
<td>4</td>
<td>2 (borderline)</td>
<td>BCC, St</td>
<td>ND</td>
</tr>
<tr>
<td>290</td>
<td>1</td>
<td>1</td>
<td>Ki, Li, Pro</td>
<td>ND</td>
</tr>
<tr>
<td>(No 15)*</td>
<td>8†</td>
<td>1</td>
<td>Thro, Pau</td>
<td>ND</td>
</tr>
<tr>
<td>291</td>
<td>3</td>
<td>1</td>
<td>Ut</td>
<td>ND</td>
</tr>
<tr>
<td>(No 5)</td>
<td></td>
<td></td>
<td>2953del3+4C</td>
<td>ND</td>
</tr>
<tr>
<td>(No 6)</td>
<td></td>
<td></td>
<td>185delAG</td>
<td>ND</td>
</tr>
<tr>
<td>337</td>
<td>5</td>
<td>1</td>
<td>Fal</td>
<td>ND</td>
</tr>
<tr>
<td>407</td>
<td>4</td>
<td>1</td>
<td>Pan, Sk</td>
<td>3450del4</td>
</tr>
<tr>
<td>442</td>
<td>1</td>
<td>1 (borderline)</td>
<td>Bl, Bl, Leu, Pan, St</td>
<td>ND</td>
</tr>
<tr>
<td>444</td>
<td>0</td>
<td>3</td>
<td>Co</td>
<td>ND</td>
</tr>
<tr>
<td>448</td>
<td>2</td>
<td>2</td>
<td>Co, Pau</td>
<td>5382InsC</td>
</tr>
<tr>
<td>461</td>
<td>7</td>
<td>0</td>
<td>Bl</td>
<td>ND</td>
</tr>
<tr>
<td>462</td>
<td>7</td>
<td>4</td>
<td>Co, Cx, Mmel</td>
<td>ND</td>
</tr>
<tr>
<td>474</td>
<td>2</td>
<td>5</td>
<td>Co, Eso, Leu</td>
<td>ND</td>
</tr>
<tr>
<td>477</td>
<td>1</td>
<td>4</td>
<td>St</td>
<td>ND</td>
</tr>
</tbody>
</table>

ND = no mutation detected.
* Number in brackets corresponds to the No of the subject tested.
† One case of male breast cancer.
BCC: basal cell carcinoma (face); Bl: bladder; Br: brain tumour; borderline ovarian cancer; Co: colon; Cx: cervix; Eso: oesophagus; Fal: fallopian tube; Ki: kidney; Leu: leukemias; Li: liver; Lu: lung; Mmel: malignant melanoma; Mye: myeloma; NHL: non-Hodgkins lymphoma; Os: osteosarcoma; Pan: pancreas; Pro: prostate; Pau: primary site unknown; Sk: skin; St: stomach; Thro: throat; Ut: uterine cancer.

D17S1327 has been located approximately 100 kb telomeric to the 5′ region of the BRCA1 gene, whereas D17S855, D17S1322, and D17S1323 have been located in in trons 8, 8, and 2, respectively. The estimated allele frequencies of these four markers have been previously reported.

Results and discussion

The 23 families studied were not tested for linkage because DNA was not available from multiple living affected subjects. Fifteen of these families contained four or more cases of breast or ovarian cancer and six families had three cases (table 1). Two families had only two cases (table 1); the nuclear family 289 was tested because the proband developed breast cancer at the age of 34 and her mother had developed ovarian cancer. In family 273 the proband was diagnosed with ovarian cancer at the age of 37 and her sister developed breast cancer at the age of 37. Cancers at sites other than breast or ovary are indicated in table 1.

In our previous mutation analysis of the BRCA1 gene in breast/ovarian cancer families ascertained in Canada, several families were found to share common haplotypes associated with the 185delAG and 5382insC mutations. Each of these two mutations represents approximately 10% of patients with BRCA1 mutations. The haplotype of the 23 probands was constructed for the same three short tandem repeat markers within the BRCA1 gene (D17S855, D17S1322, and D17S1323) and with one marker approximately 100 kb telomeric to the gene (D17S1327).

The D17S1327 allele O was detected in the probands of families 289 and 448. The frequency of this rare allele was estimated to be less than 0.01% and has been detected only in patients bearing the mutation 5382insC. As predicted, both proband No 5 in family 289 and patient No 22 in family 448 were carriers of the 5382insC mutation, as shown by direct sequencing (fig 1). Unfortunately, it was impossible to test for the presence of the 5382insC mutation in colon cancer cases No 4 and No 5 of family 448 because DNA samples were not available. Moreover, it is of interest to note that the haplotype D, E, F, M/O of the proband in family 289 is consistent with the haplotype D, E, F, O which is shared in 19 out of 21 subjects studied bearing the 5382insC mutation. However, the haplotype E, C/E, F, H/O detected in the index case of family 448 indicates a discrepancy at the D17S855 marker owing to the presence of the E allele, which is a base pair shorter than the D allele. The most likely explanation for this observation is a single mutation occurring at D17S855, as previously observed in the index case of family MICH205, who has the haplotype E, D/E, F, O. It has been estimated that the mutation 5382insC has occurred 38 generations ago (90% limits 18-69).

The 185delAG mutation has been detected in several Ashkenazi Jewish breast and ovarian cancer families from Canada and other countries. It has been estimated that this mutation, which has a frequency of about 0.01%, occurred 46 generations ago (90% limits 23-80). None of the haplotypes of the index cases tested was consistent with the haplotype of those bearing the mutation 185delAG and this mutation was not detected by direct sequencing in these 23 people initially selected. However, in proband No 5 of family 291, we analysed the coding region and exon-intron boundaries of the BRCA1 gene by direct sequencing of the PCR products. No mutation was found in this person who had unilateral breast cancer diagnosed in her 50s. Thereafter, we learned that a branch of this family consisting of subjects 1, 2, 4, 5, and 6 (fig 2) are of Ashkenazi Jewish descent. This information, combined with the haplotype analysis, suggested the possibility that the proband No 11 may be a carrier of the 185delAG mutation. We then sequenced exon 2 of the BRCA1 gene from adult No 11 and found the 185delAG mutation. Furthermore, haplotype analysis of the father of No 11 (No 8) suggested that the mutation has been inherited from his mother (No 9). Our data, combined with the clinical presentation of the family members, suggest that this mutation may account for some cases of breast and ovarian cancer in this family and that the breast cancer case No 5 was a sporadic case. It is also of interest to note that the uterine cancer case No 6 in family 291 is not a carrier of the 185delAG mutation, as deduced by haplotype analysis.
Dideoxy fingerprinting coupled with direct sequencing analyses showed the presence in exon 11 of the novel frameshift mutation 2953del3+C in heterozygote No 18 in family 290. This screening method is a hybrid between single stranded conformation polymorphism (SSCP) analysis and Sanger dideoxy sequencing involving sequencing reaction with one labelled dideoxynucleotide followed by non-denaturing polyacrylamide gel electrophoresis.\(^9\)\(^{10}\) In addition to being more sensitive than SSCP, this method offers the opportunity to amplify larger fragments (fig 4). The mutation 2953del3+C detected in fig 4 was sequenced and shown to be caused by the deletion of the last two nucleotides of codon 945 and the first nucleotide of codon 946 coupled with the insertion of a C generating a premature termination codon at 950 (fig 3). This peculiar novel frameshift mutation was identified in the proband who had developed breast cancer at the ages of 37 and 38 and kidney cancer at the age of 38. This mutation is the first BRCA1 mutation that we found in a French Canadian family. This mutation was not detected in her mother (No 15) and therefore, barring de novo mutation, is deduced to be of paternal origin. This hypothesis is consistent with three breast cancers in this branch of the family. It is unfortunate that we do not have any DNA sample available from additional subjects affected with cancer in this family. The maternal family history is notable for a case of male breast cancer, several female breast cancers, throat cancer, and prostate cancers. All these cancers have been associated with BRCA2. It remains possible that the proband is a carrier of a mutation in both genes; it is therefore premature to attribute the renal cancer to the BRCA1 mutation.

In the 18 families in which mutations were not detected, only five were clear examples of

and confirmed by direct sequencing analysis. Also, haplotype analysis of cases No 5 and No 6 suggest that they might carry different BRCA1 alleles (data not shown).

The presence of a novel frameshift mutation in exon 11 designated 3450del14 was detected in heterozygote No 17 of family 407 (fig 3). This mutation is the result of the deletion of codon Gln1111 (CAA) and the first nucleotide (G) of codon 1112 and produces a premature termination codon at position 1115. This women developed breast cancer at the age of 29 and a second primary cancer of the ovary at the age of 34, whereas her sister developed breast cancer at the age of 29. The detection of breast cancer in her mother, diagnosed at the age of 40, and the presence of a maternal relative who developed breast cancer at the age of 26 suggest that this novel frameshift mutation was inherited from her mother.

Figure 1 Detection of the frameshift mutation 5382insC in two families. Panel A: pedigrees of families 289 and 448. Br: breast cancer, Ov: ovarian cancer, Co: colon cancer, Psa: primary site unknown. The numbers following these abbreviations indicate age at diagnosis. The probands carrying the 5382insC mutation in these families are indicated with an arrow. The subject numbers are shown below the symbols. Panel B: autoradiograms show only the partial nucleotide sequence obtained by direct sequencing of PCR products and corresponding amino acids of the sense strand of the BRCA1 region including the frameshift mutation 5382insC.

Figure 2 Pedigree of family 291. Br: breast cancer, Ov: ovarian cancer, Ut: uterine cancer. The numbers following these abbreviations indicate age at diagnosis. The subject numbers are shown below the symbols. Adult No 11 in this pedigree bearing the 185delAG mutation is indicated with an arrow, whereas this mutation was not found in the initial index case No 5 or her sister No 6 who are indicated with an asterisk.
the breast/ovarian syndrome (two or more cases each of breast and ovarian cancer). It is expected that the majority of families of this type are the result of BRCA1. We cannot rule out the possibility that some mutations were located within regions not screened in the BRCA1 gene leading, for example, to aberrantly spliced mRNA species, a lower level of BRCA1 gene expression, or transcript instability, which may account for 15-20% of disease associated mutations. However, four of the above mentioned families were unusual in that there was a remarkable number of cancers of other sites in these families, including the brain, bladder, kidney, lung, prostate, thyroid, pancreas, and colon. It may be that the appearance of cancer of multiple other sites is characteristic of cancer susceptibility genes other than BRCA1. Studies to verify the involvement of BRCA2, a second breast cancer susceptibility gene mapped to 13q12-13, are under way in these families. In addition, the high frequency of sporadic breast and ovarian cancer suggests the possibility that we may have studied a sporadic case, as was found with family 291.

The two families with borderline ovarian cancers (285 and 442) were negative for the BRCA1 mutation. This is in keeping with our earlier observation that borderline tumours are not part of the hereditary ovarian cancer spectrum.

The two families with breast/ovarian cancers (285 and 442) were negative for the BRCA1 mutation. This is in keeping with our earlier observation that borderline tumours are not part of the hereditary ovarian cancer spectrum. Also, we studied two families (337 and 461) with breast cancer and cancer of the fallopian tube, following our observation of a BRCA1 mutation segregating in a family with cancer of the fallopian tube. Surprisingly, both families were negative for BRCA1 mutations.

BRCA1 mutations were thus found in only five of 23 families tested. However, in contrast to our previous study of families ascertained in Canada, there were no linkage data supporting the presence of a BRCA1 mutation in these families. Where possible, we currently look for evidence of linkage to the BRCA1 locus at 17q21 or the BRCA2 locus at 13q12-q13 before proceeding to sequencing analysis,
which is time consuming and technically challenging. However, although there is no evidence that there is clustering of BRCA1 mutations, it may be appropriate to use initial and rapid alternative screening procedures as recently developed.1

We thank Martine Tranchant, Carolle Samson, and Carole Bélanger for their expert assistance and Dr David Rosebush and Harriet Gaynor for the detection of the mutation 185delAG in family 921. We also thank physicians who contributed to this study, including Drs. R. Marguerite, D. Coles, J. Gilchrist, B. McIllivray, B. Rosen, J. Buchanan, J. Warner, M. Pollock, and R. Carrer, as well as the family members for their much appreciated cooperation. This work was supported by a Medical Research Council (MRC) of Canada grant to JS, Endocrinology Branch, Myriad Genetics, and the Canadian Genetic Disease Network (Federal NCE Program) and the Fonds de la Recherche en Santé du Québec (FRSQ) and the US Army Grant DAMD17-94-5-4299. FB is recipients of a Studentship from the MRC, JS is a MRC scholar, SN is supported by the Canadian Breast Cancer Foundation Ontario Chapter, and PT is a MRI-CSR Scholar.


